Semiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responses.

Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer (2001) 2.82

High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol (1999) 2.80

Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64

CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res (2003) 2.40

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest (1997) 2.39

Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood (2002) 1.82

Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A (2001) 1.80

Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer (2001) 1.53

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother (2004) 1.48

DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol (2004) 1.22

Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol (2010) 1.12

Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun (2004) 1.12

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol (2003) 1.11

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10

Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med (1996) 1.07

SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res (2009) 1.02

Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol (2003) 1.02

A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother (2001) 1.00

Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study. Oncol Rep (2007) 0.98

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res (2005) 0.96

Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine (2005) 0.94

Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat (2006) 0.91

Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol (2008) 0.91

Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol (2010) 0.86

Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine (2007) 0.85

Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol (2003) 0.84

Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbecks Arch Surg (2010) 0.82

Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology (1999) 0.79

Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol (2000) 0.77

Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro. Tissue Antigens (2006) 0.76

Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64

Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer (2010) 1.14

Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol (2009) 1.14

Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun (2004) 1.12

Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One (2012) 1.06

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett (2008) 1.02

Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS One (2012) 1.02

Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol (2003) 1.02

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells. J Cancer Res Clin Oncol (2007) 0.99

MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes Cancer (2015) 0.97

Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. Int J Cancer (2007) 0.97

Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet (2006) 0.94

An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes. PLoS One (2011) 0.93

Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J (2011) 0.92

Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. Cancer Res (2009) 0.92

Impact of portal branch ligation on tissue regeneration, microcirculatory response and microarchitecture in portal blood-deprived and undeprived liver tissue. Microvasc Res (2011) 0.91

WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer (2004) 0.91

COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther (2012) 0.89

Human endogenous retroviruses and cancer: causality and therapeutic possibilities. World J Gastroenterol (2012) 0.88

Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer (2010) 0.86

Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cell Immunol (2011) 0.86

Bacteriolytic therapy of experimental pancreatic carcinoma. World J Gastroenterol (2010) 0.85

Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunol Immunother (2011) 0.84

Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison. PLoS One (2013) 0.83

Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbecks Arch Surg (2010) 0.82

Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine (2005) 0.82

Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer (2004) 0.81

Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. Int J Oncol (2011) 0.81

Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis. Oncotarget (2014) 0.81

Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma. Int J Cancer (2005) 0.81

The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol (2004) 0.80

The "North German Tumor Bank of Colorectal Cancer": status report after the first 2 years of support by the German Cancer Aid Foundation. Langenbecks Arch Surg (2013) 0.80

Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. J Lipid Res (2013) 0.80

Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma. Pancreas (2007) 0.79

Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model. Eur Surg Res (2006) 0.79

Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunol Immunother (2013) 0.79

Combining bacterial-immunotherapy with therapeutic antibodies: a novel therapeutic concept. Vaccine (2012) 0.78

Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur J Cancer (2006) 0.78

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. J Cancer Res Clin Oncol (2013) 0.77

Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clin Chem Lab Med (2015) 0.77

Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp Hematol (2010) 0.77

Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who? Oncoimmunology (2013) 0.76

The impact of pyrvinium pamoate on colon cancer cell viability. Int J Colorectal Dis (2014) 0.76

A novel sialyl Le(X) expression score as a potential prognostic tool in colorectal cancer. World J Surg Oncol (2012) 0.76

CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions. Cancer Res (2002) 0.76

Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol Ther (2015) 0.76

Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma. BMC Immunol (2011) 0.76

Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg (2011) 0.76

Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. Int J Cancer (2002) 0.75

Microdensitometry of osteopontin as an immunohistochemical prognostic biomarker in colorectal carcinoma tissue microarrays: potential and limitations of the method in 'biomarker pathology'. Histopathology (2012) 0.75

The EpCAM high/CD44 high colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. Histopathology (2010) 0.75

Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer--a meta-analysis and current overview. Int J Colorectal Dis (2015) 0.75